BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 11565870)

  • 1. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.
    Nagane M; Levitzki A; Gazit A; Cavenee WK; Huang HJ
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5724-9. PubMed ID: 9576951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH; Song YC; Kim SH; Jo H; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.
    Zhang Y; Xing X; Zhan H; Li Q; Fan Y; Zhan L; Yu Q; Chen J
    J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):773-778. PubMed ID: 22173497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.
    Ellis AG; Doherty MM; Walker F; Weinstock J; Nerrie M; Vitali A; Murphy R; Johns TG; Scott AM; Levitzki A; McLachlan G; Webster LK; Burgess AW; Nice EC
    Biochem Pharmacol; 2006 May; 71(10):1422-34. PubMed ID: 16522318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
    Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
    Chakravarti A; Loeffler JS; Dyson NJ
    Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility.
    Pedersen MW; Tkach V; Pedersen N; Berezin V; Poulsen HS
    Int J Cancer; 2004 Feb; 108(5):643-53. PubMed ID: 14696090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
    Halatsch ME; Gehrke EE; Vougioukas VI; Bötefür IC; A-Borhani F; Efferth T; Gebhart E; Domhof S; Schmidt U; Buchfelder M
    J Neurosurg; 2004 Mar; 100(3):523-33. PubMed ID: 15035290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.
    Lal A; Glazer CA; Martinson HM; Friedman HS; Archer GE; Sampson JH; Riggins GJ
    Cancer Res; 2002 Jun; 62(12):3335-9. PubMed ID: 12067969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.